Clinical trial · Interventional
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
NCT00170677CI-TRIAL-00014509completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Topotecan | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- A
- interventionNames
- Drug: Topotecan
- type
- EXPERIMENTAL
- label
- B
- interventionNames
- Drug: Topotecan
Primary outcomes (1)
- measure
- Rate of CR and PR in each arm
- timeFrame
- every 12 weeks
Secondary outcomes (2)
- measure
- Toxicity of topotecan treatment
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with histologically-confirmed ovarian cancer * relapse within 6 month after primary therapy * primary therapy with platin and taxan * ECOG 0-2 * \>= 18 years * leukocytes \>= 3.000/ µl * platelet \>= 100.000/ µl * neutrophil \>= 1.500/ µl * written informed consent Exclusion Criteria: * earlier topotecan therapy * simultaneous or planned radiotherapy * secondary malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.